Researchers have developed a new all-in-one vaccine aimed at priming the body to respond to a range of different strains of coronaviruses, including the ones not yet known. The researchers from Cambridge, MIT and CalTech published their findings recently in Nature Nanotechnology. Their vaccine was successfully tested on mice and will likely enter human clinical trials […] Continue reading ->
Insulin pens are more affordable and preferred by diabetics but they are available almost exclusively in high-income countries due to gross overpricing, according to a report by Médecins Sans Frontières (MSF) and T1International, a British NGO fighting for equal treatment access for people with diabetes type 1. The research was presented on Wednesday, ahead of […] Continue reading ->
The government of Colombia has issued its first-ever compulsory license to enable access to generic versions of the key HIV medicine dolutegravir, without permission from the patent owner, ViiV Healthcare. Dolutegravir is recommended as part of the preferred first-line antiretroviral treatment regimen for people living with HIV, including during pregnancy, as per the guidance of […] Continue reading ->
Pharmacogenomics research in Africa transcends mere regional healthcare improvements: it represents a pivotal step in addressing pressing global health challenges and propelling medical science forward for all.  A revolution is sweeping through the field of medicine, redefining how we approach the treatment of diseases. Africa must not be left behind in this transformative journey. Pharmacogenomics, […] Continue reading ->
Amidst the anticipated increase in vaccine-preventable diseases as the global population ages, a first-of-its-kind study has underscored the dual benefits of adult immunization programs. Beyond saving lives and preventing severe illnesses, the study found these programs offer substantial financial advantages to nations by reducing the need for costly hospitalizations and emergency medical interventions and avoiding […] Continue reading ->
“Disappointed” is how the Africa Centres for Disease Control and Prevention phrased its response to pharmaceutical company Moderna “pausing” its Kenyan mRNA vaccine manufacturing facility.  Moderna’s decision is yet another example of how complex it is to kickstart vaccine manufacturing on the continent – an essential component to safeguard Africans against future pandemics on the […] Continue reading ->